24 recruiting. 24 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 24 | Recruiting 24 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire Gazelle-Multispectral point of care testing for newborn sickle cell disease screening; and initiation of early comprehensive clinical interventions - Sickle Cell Disease (SCD) | Phase 4 | Recruiting | Swiss Tropical & Public Health Institute | 120 | 2026-07-27 | 2026-10-05 |
| Anemia Therapy in Patients With Infective Endocarditis Adjunctive anemia therapy - Infective Endocarditis (IE), Severe Anemia | Phase 4 | Recruiting | Copenhagen University Hospital, Rigshospitalet | 74 | 2026-05-15 | 2026-05-29 |
| Tranexamic Acid for Bleeding Reduction During TURP Surgery Tranexamic Acid, Placebo (Normal Saline) - Benign Prostatic Hyperplasia, Transurethral Resection of the Prostate | Phase 4 | Recruiting | Hamza Najout | 80 | 2026-03-30 | 2026-10-09 |
| Acupoint TENS vs Resistance Training for Iron Deficiency Anemia Acupuncture transcutaneous electrical nerve stimulation (Acu-TENS), Resistance exercise training, Ferrous Sulfate - Iron Deficiency Anemia | Phase 4 | Recruiting | Cairo University | 60 | 2026-01-15 | 2026-05-26 |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS Ravulizumab - aHUS, Atypical Hemolytic Uremic Syndrome | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2025-12-19 | 2026-04-20 |
| Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women Sucrosomial® Iron (Sideral® Forte), Ferric Maltol (Feraccru®) - Anemia, Iron Deficiency Anemia (IDA) | Phase 4 | Recruiting | Pharmanutra S.p.a. | 146 | 2025-12-11 | 2026-09-03 |
| Post-discharge Malaria Chemoprevention Implementation Trial in Benin Adherence support strategy A, Adherence support strategy B, Control - Severe Malaria, Severe Anaemia | Phase 4 | Recruiting | Institut de Recherche Clinique du Benin | 648 | 2025-07-02 | 2026-08-12 |
| Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease Depot medroxyprogesterone acetate (DMPA) - Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 4 | Recruiting | University of Pennsylvania | 65 | 2025-06-26 | 2026-11-05 |
| The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery Ferric Derisomaltose, Saline (NaCl 0,9 %) (placebo) - Hip Fracture, Anemia | Phase 4 | Recruiting | Soren Overgaard | 210 | 2025-06-09 | 2026-06-01 |
| Oral Iron Supplementation on Alternate vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill, alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill - Iron-deficiency Anemia (IDA), Pregnancy | Phase 4 | Recruiting | Southern Illinois University | 120 | 2025-05-27 | 2026-04-24 |
| Use of Pegmolesatide in Renal Anemia: Efficacy and Safety of Switching to Pegmolesatide in Non-dialysis CKD Patients Treated With rhuEPO or HIF-PHI Pegmolesatide - Renal Anemia in Non-dialysis Chronic Kidney Disease | Phase 4 | Recruiting | The First Affiliated Hospital of Dalian Medical University | 160 | 2025-05-01 | 2026-09-02 |
| Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease Enarodustat - Chronic Kidney Disease Associated Anemia | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 1670 | 2025-03-27 | 2025-07-28 |
| Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) PK-optimized oral hydroxyurea at MTD until 15 years of age. - Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0) | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 50 | 2024-12-19 | 2025-09-16 |
| Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial Iron, EPO, 0.9 % NaCl - Anemia, Sepsis | Phase 4 | Recruiting | Piotr Czempik | 200 | 2024-11-10 | 2024-12-27 |
| Stroke Prevention in Nigeria 2 Trial Hydroxyurea - Sickle Cell Disease, Stroke | Phase 4 | Recruiting | Vanderbilt University Medical Center | 220 | 2024-08-05 | 2026-03-05 |
| Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days, Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose). - Vivax Malaria, G6PD Deficiency | Phase 4 | Recruiting | Menzies School of Health Research | 100 | 2024-05-17 | 2026-03-12 |
| Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure Sucrosomial iron, Placebo - Chronic Heart Failure, Iron-deficiency | Phase 4 | Recruiting | Raffaele De Caterina | 60 | 2024-03-14 | 2025-10-01 |
| Iron Deficiency Anemia (IDA) and the Brain Ferric derisomaltose, NovaFerrum - IDA - Iron Deficiency Anemia, Anemia | Phase 4 | Recruiting | Children's Hospital Los Angeles | 120 | 2023-12-07 | 2024-10-30 |
| Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia Venofer 200 MG Per 10 ML Injection, Ferinject - Anemia, Iron Deficiency, Pregnancy Anemia | Phase 4 | Recruiting | Western Galilee Hospital-Nahariya | 200 | 2023-11-02 | 2026-09-11 |
| Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma Iron-Dextran Complex Injection [InFed], Saline Placebo - Acute Blood Loss Anemia, Fracture | Phase 4 | Recruiting | Oregon Health and Science University | 150 | 2022-06-01 | 2025-08-08 |
Showing 20 of 24. Sign in to see all of them.
Anemia, Iron-Deficiency (8) · Anemia, Sickle Cell (5) · Iron Deficiencies (2) · Renal Insufficiency, Chronic (2) · Atypical Hemolytic Uremic Syndrome (1) · Endocarditis (1) · Fractures, Bone (1) · Glucosephosphate Dehydrogenase Deficiency (1) · Heart Failure (1) · Hip Fractures (1) · Inflammation (1) · Malaria (1) · Malaria, Vivax (1) · Motor Activity (1)
Hematologic Diseases (24) · Hemic and Lymphatic Diseases (24) · Metabolic Diseases (9) · Nutritional and Metabolic Diseases (9) · Anemia, Hypochromic (8) · Iron Metabolism Disorders (8) · Anemia, Hemolytic (7) · Anemia, Hemolytic, Congenital (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Iron Deficiencies (6) · Hemoglobinopathies (5) · Male Urogenital Diseases (4) · Pathologic Processes (4)
Sodium Chloride (3) · ferric derisomaltose (3) · ferrous sulfate (3) · Iron (2) · Iron-Dextran Complex (2) · Aging (1) · Ascorbic Acid (1) · Ferric Oxide, Saccharated (1) · Ferrosoferric Oxide (1) · Hydroxyurea (1) · Injections (1) · Maximum Tolerated Dose (1) · Pharmacogenomic Variants (1) · Primaquine (1) · Resistance Training (1)
Alexion Pharmaceuticals, Inc. (1) · Cairo University (1) · Children's Hospital Los Angeles (1) · Children's Hospital Medical Center, Cincinnati (1) · Copenhagen University Hospital, Rigshospitalet (1) · Hamza Najout (1) · Institut de Recherche Clinique du Benin (1) · Menzies School of Health Research (1) · Novartis Pharmaceuticals (1) · Oregon Health and Science University (1) · Pharmanutra S.p.a. (1) · Piotr Czempik (1) · Raffaele De Caterina (1) · Shanghai Zhongshan Hospital (1) · Soren Overgaard (1)
United States (8) · Brazil (2) · China (2) · Denmark (2) · Italy (2) · Spain (2) · Belgium (1) · Benin (1) · Colombia (1) · Côte d’Ivoire (1) · Egypt (1) · Ethiopia (1) · France (1) · Germany (1) · Israel (1)
Andrea Roe, MD MPH (1) · Charles T. Quinn, Professor of Pediatrics, M.D., M.S. (1) · Dina Ebrahim Mohamed Aboshady, BSc PT (1) · Gabriele Masini, MD PhD (1) · Henning Bundgaard, Professor, Dr. med (1) · Hongli Lin, M.D. (1) · Jenny Hill, MSc, PhD (1) · John Wood, MD, PhD (1) · Mia Marie Pries-Heje, MD, PhD (1) · Michael R DeBaun, MD, MPH (1) · Nagwa Mohamed Hamed Badr, PhD (1) · Nicolas Tekin Jones, MD (1) · Oleh Akchurin, M.D. (1) · Peter Noordzij, MD, PhD (1)
PMID 36944463, PMID 37885026, PMID 42442814, PMID 42665339
2025 (1), R01HL175726 (1), R01NS117430 (1), U01NS129143 (1)